Where does Switzerland stand? Where is it heading? Its developments are my focus. Six months ago, the United Nations General Assembly asked Switzerland to organise a conference on the fourth ...

The following is a summary of “Validation of the Boston Criteria Version 2.0 for Cerebral Amyloid Angiopathy in Patients Presenting With Intracerebral Hemorrhage,” published in the March 2025 issue of ...

A while back, I had a bone density scan to assess how strong my bones were, and I was shocked by the results. The early menopause I had been put into as treatment for my breast cancer, as well as the ...

Are you someone who struggles to sleep due to nighttime anxiety or stress? Studies show that the best weighted blankets are clinically proven to manage your mood, induce a sense of calm and even ...

Cerebral amyloid angiopathy (CAA ... Out of 31 patients, 28 had susceptibility weighted imaging or susceptibility weighted angiographyand 3 had gradient echo as their T2*‐weighted susceptibility ...

AUSTIN, Texas, March 03, 2025--SolarWinds (NYSE:SWI), a leading provider of simple, powerful, secure observability and IT management software, today announced that it has signed an agreement to ...

Side imaging fish finders have found their way into every tournament angler’s boat. The ability to scan for structure, weed edges, and fish helps anglers stay dialed. Side imaging works ...

Taylor Swift and Travis Kelce are back in the US after enjoying a private, romantic getaway together. A source exclusively tells Page Six that the pop superstar and the Kansas City Chiefs tight ...

If you struggle with falling (and staying) asleep, a weighted blanket can be a useful accessory to help you enjoy a better night’s slumber. That’s because the added weight can help reduce ...

In its fourth quarter 2024 investor letter, Voss Capital emphasized stocks such as SolarWinds Corporation (NYSE:SWI). SolarWinds Corporation (NYSE:SWI) is a technology company that offers IT ...

But in just the past year and a half, two anti-amyloid drugs—lecanemab (Leqembi) and donanemab (Kisunla)—that can slow the progression of early Alzheimer’s disease have been approved in the US.